487 results on '"Trneny, M"'
Search Results
152. Favorable Outcome of High-Risk Mediastinal Diffuse Large B-Cell Lymphoma (DLBCL) after Dose-Intensive Chemotherapy, Rituximab and Autologous Transplant (ASCT).
153. Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab -early stopping after the first interim analysis
154. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.
155. AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS.
156. POST HOC ANALYSES OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA WHO RECEIVED LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO (AUGMENT).
157. Aleukemic granulocytic sarcoma with AML1/ETO fusion gene expression and clonal T cell populations
158. DOWN-REGULATION OF MI R-150 AND UP-REGULATION OF ITS TARGET FOXP1 IS ASSOCIATED WITH TRANSFORMATION OF FOLLICULAR LYMPHOMA.
159. Impact of pre-transplant rituximab and PET on clinical outcome after autologous stem cell transplantation for diffuse large B-cell lymphoma
160. B-Cell development stage of bcl-1 and bcl-2 /IgH translocation does not effect clinical characteristics and outcome of follicular lymphoma and mantle cell lymphoma patients
161. OUTCOME OF CYTOGENETICS IN PATIENTS WITH NEWLY DIAGNOSED EXTRAMEDULLARY MYELOMA UNDERGOING STEM-CELL TRANSPLANTATION
162. ENDOTHELIAL CELLS AND ENDOTHELIAL PRECURSOR CELLS KINETICS IN HAEMATOLOGICAL PATIENTS UNDERGOING CHEMOTHERAPY OR AUTOLOGOUS STEM CELL TRANSPLANTATION
163. Mantle Cell Lymphoma Prognostic Index and proliferative activity are strong prognostic markers in clinical practice: A retrospective study on 235 patients of the Czech Lymphoma Study Group
164. High-dose immunoablation and stem cell transplantation in multiple sclerosis patients: ten-year experience in the Czech Republic
165. POSITIVITY OF WHOLE BODY POSITRON EMISSION TOMOGRAPHY (PET) BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION HAS NEGATIVE PROGNOSTIC IMPACT BUT IT DIFFERS ACCORDING TO LYMPHOMA SUBTYPE AND LINE OF ASCT
166. Long-time follow-up of CD4+T-cells in peripheral blood after autologous haematopoietic stem cell transplantation in multiple sclerosis patients
167. CLONAL EVOLUTION STUDIED BY I-FISH IN B-CLL
168. CD10 EXPRESSION IN LYMPH NODE STROMAL CELLS DOES NOT SIGNIFICANTLY INFLUENCE GENE EXPRESSION ANALYSIS OF CD10 POSITIVITY OR NEGATIVITY OF A TUMOR
169. PATTERN OF ANGIOGENESIS-RELATED GENE EXPRESSION DURING IN VIVO GROWTH OF MANTLE CELL LYMPHOMA CELL LINE JEKO-1
170. Molecular and clinical study of CLL/SLL patients with both alleles for immunoglobulin heavy chain gene rearranged: What is a true biclonality?
171. Immunoablative therapy with autologous stem cell support in the treatment of 25 patients with poor risk multiple sclerosis
172. Immunoablative therapy with autologous stem cell support in the treatment of patients with poor-risk multiple sclerosis
173. THE QUALITY OF LIFE FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - THE RETROSPECTIVE STUDY OF CZECH TRANSPLANT CENTRES
174. Growth and differentiation of mesenchymal stem cells in human sera
175. The incidence of pulmonary and bronchial infections in patients after haematopoietic stem cell transplantation performed in HEPA or non-HEPA filtered rooms - observational study - interim results
176. IMPACT OF PRIOR TREATMENT ON PFS FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS RANDOMIZED TO LENALIDOMIDE VS INVESTIGATOR'S CHOICE: A SUBGROUP ANALYSIS OF THE PHASE II MCL-002 (SPRINT) STUDY
177. Decrerased transplant related mortality and older patients in 20-years autologous stem cell transplantation programm, single centre results
178. Combined molecular biological and molecular cytogenetic analysis of genomic changes in 146 patients with B-cell chronic lymphocytic leukemia
179. Autologous stem cell transplantation with in vitro purged or unpurged graft in the treatment of 25 patients with poor-risk multiple sclerosis
180. Xenogeneic protein-free cultivation of mesenchymal stromal cells - Towards clinical applications
181. Establishment and characterization of new Diffuse Large B-Cell Lymphoma (DLBCL) cell lines, cell line-based and primary DLBCL cell-based mouse xenograft models
182. FIFTY PERCENT CURE RATE IN POOR RISK RELAPSED/REFRACTORY HODGKIN LYMPHOMA AFTER TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION
183. NEW PROGNOSTIC MARKERS OF CHRONIC LYMPHOCYTIC LEUKEMIA IN THE EVERYDAY HEMATOLOGICAL PRACTICE. A MULTICENTER ANALYSIS
184. Novel Cytokines and their possible role in supportive care | Nove cytokiny a jejich mozne uplatneni v podpurne lecbe
185. Pet findings after therapy during follow-up in patients with Hodgkin lymphoma - A retrospective study
186. THE TREATMENT MODIFICATION DOES NOT SEEM TO CHANGE THE DLBCL PATIENT'S OUTCOME WHEN CORRELATED WITH EARLY PET RESULTS
187. Case-report: no evidence of disease activity in neuromyelitis optica patient 5 years after allogeneic hematopoietic stem cells transplantation
188. PET positivity predicts failure of HDT and ASCT in the relapse setting but not in the first line treatment
189. ENDOTHELIAL CELLS (EC) AND ENDOTHELIAL PRECURSOR CELLS (EPC) KINETICS IN HAEMATOLOGICAL PATIENTS UNDERGOING CHEMOTHERAPY OR AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)
190. PILOT STUDY TO ASSESS REAGENT AND INSTRUMENT QUALITY FOR REPRODUCIBLE DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA: AN ESCCA AND ERIC HARMONISATION PROJECT
191. Unusual sequence of VDJ rearrangement revealed by molecular analysis in a patient with indolent lymphoma
192. EXPRESSION OF CD66ABCE ON TUMOR CELLS IN NON-HODGKIN LYMPHOMAS AND MULTIPLE MYELOMA
193. A 'single' dose G-CSF after PBSCT in patients with malignant lymphoma - an interim analysis of multicenter randomized trial comparing standard schedule with delayed application and placebo
194. MDS development risk in CLL patients with prolonged cytopenia after fludarabine, cyclophosphamide and rituximab (FCR) regime
195. Assessing Bone Marrow Involvement in DLBCL: Comparison of FDG PET and Bone Marrow Biopsy
196. The quality of life following haematopoietic stem cell transplantation, retrospective study of Czech transplant centres, the first interim analysis
197. A 'single' dose of G-CSF after autologous stem cell transplantation in patients with malignant lymphoma - second interim analysis of multicentre randomised trial comparing standard schedule with delayed application and placebo
198. The survival benefit of intensified induction and/or high-dose (HDT) consolidation in high-risk diffuse large B-cell lymphoma (DLBCL) patients: Data from the Czech Lymphoma Study Group database
199. Long-term follow-up of CD4+T cells in peripheral blood and CSF after autologous hematopoietic stem cells transplantation in multiple sclerosis patients
200. LIMITED NUMBER OF GENES DISTINGUISHES BETWEEN GERMINAL CENTRE-LIKE AND NONGERMINAL CENTRE-LIKE DIFFUSE LARGE B CELL LYMPHOMA
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.